Lombard Medical (OTCMKTS: EVARF) and Meridian Bioscience (NASDAQ:VIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Insider & Institutional Ownership
39.9% of Lombard Medical shares are owned by institutional investors. Comparatively, 85.4% of Meridian Bioscience shares are owned by institutional investors. 2.7% of Meridian Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Lombard Medical has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
This is a summary of current ratings and target prices for Lombard Medical and Meridian Bioscience, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Meridian Bioscience has a consensus price target of $16.00, indicating a potential upside of 10.34%. Given Meridian Bioscience’s higher probable upside, analysts clearly believe Meridian Bioscience is more favorable than Lombard Medical.
Valuation & Earnings
This table compares Lombard Medical and Meridian Bioscience’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Lombard Medical||$12.17 million||0.21||-$31.03 million||($1.54)||-0.06|
|Meridian Bioscience||$200.77 million||3.06||$21.55 million||$0.57||25.44|
Meridian Bioscience has higher revenue and earnings than Lombard Medical. Lombard Medical is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.
Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.4%. Lombard Medical does not pay a dividend. Meridian Bioscience pays out 87.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
This table compares Lombard Medical and Meridian Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Meridian Bioscience beats Lombard Medical on 13 of the 14 factors compared between the two stocks.
Lombard Medical Company Profile
Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
Receive News & Ratings for Lombard Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical and related companies with MarketBeat.com's FREE daily email newsletter.